BioSpace News Archive

The non-profit, Freedom to Operate (FTO), has just published new research on the polymorphic form of LSD D-tartrate, a common salt form of LSD.

Dynarex Corporation, a leading durable medical equipment and disposable medical products company, is proud to unveil its newly extended line of premium respiratory therapy supplies—Dynarex Resp-O2™.

Awakn Clinics Bristol was Awakn’s and the UK’s first medical psychedelic-assisted therapy clinic.

Today it announces that in the event that the existing criteria of a time to result of 30-minutes is not met by September 2022, tests with a time to result of 60-minutes or less will be eligible. This remains a dramatic reduction from the three days it currently takes from test to result.

Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults.

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced that data from a Phase 2a trial of the investigational, novel gene therapy, URO-902, will feature as a late-breaker at the 2022 annual meeting of the American Urological Association, May 13-16, in New Orleans, Louisiana.

OcyonBio, LLC’s client Biosimilar Solutions, Inc., announces it has started its registrational clinical trials for the biosimilar version of Neulasta Filgrastim, a granulocyte-colony stimulating factor.

With this certification, PMLS is regarded as one of the world’s top-ranked labs for medical diagnostics which exceeds the industry’s clinical laboratory standards.

At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

Merit Medical Systems, Inc. (NASDAQ: MMSI), announced today that it will release its financial results for the quarter ended March 31, 2022, after the close of the stock market on Wednesday, April 27, 2022.